Related Experiment Video
Updated: May 28, 2025

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay
Published on: April 3, 2009
Dataset of transcriptomic changes induced by naringenin treatment in MCF-7 breast cancer cells
Van T Hoang1,2, Mackenzie L Hawes1,2, Jack R Elliott1,2
1Tulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Abstract:
Naringenin (Nar) is a citrus fruit-derived phytoestrogen, a group of dietary compounds produced by a wide variety of plants. Due to structural similarity to 17-β-estradiol (E2), phytoestrogens can bind to estrogen receptors (ERs) to exert context-dependent estrogenic and/or anti-estrogenic effects. As such, there are potential health benefits and risks associated with phytoestrogen exposure. To investigate the effects of Nar in breast cancer, based on its activity as a phytoestrogen, we treated MCF-7 ER-positive (ER+) breast cancer cells with Nar (10 µM) and examined transcriptomic changes in MCF-7 cells induced by Nar treatment. Pathway analysis included in our dataset shows upregulation of genes associated with estrogen signaling and epithelial-to-mesenchymal transition in breast cancer cells treated with naringenin.

